On July 5, 2021, Telo Genomics Corp. (TSXV:TELO) closed the transaction. The company has issued 390,000 units for the gross proceeds of CAD 195,000 in its second and final tranche. The company has raised CAD 2,287,750 in the transaction. A director of the Company participated in the transaction by subscribing for 10,000 Units. Each warrant issued in the transaction will entitle the holder to acquire one additional Common Share at a price of CAD 0.75 per Common Share until January 2, 2023. The company has paid CAD 10,150 to PI Financial Corp. and CAD 3,500 to Canaccord Genuity Corp. The Company also issued finder's warrants to eligible finders as follows 20,300 finder's warrants to PI Financial Corp. and 7,000 finder's warrants to Canaccord Genuity Corp. Each finder's warrant entitles the holder to acquire one common share of the Company at a price of CAD 0.50 per share until July 2, 2022. The securities issued pursuant to this tranche of the Offering are subject to a statutory four month hold period ending on November 3, 2021 in accordance with applicable securities laws. The company issued CAD 99,994.792 ($80,680) in pursuant to exemption provided under Regulation D. The company intends to continue the transaction for more than one year.